Alkermes plc. (ALKS) 8-K Current Report: February 25, 2026
Filed: February 25, 2026
Health Care
Pharmaceutical PreparationsAlkermes plc. (ALKS) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
Alkermes plc. 8-K Feb 25, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • CEO Richard F. Pops retiring July 31, 2026 after 35 years, transitioning to Senior Advisor through December 31, 2026 and non-executive Chairman role
- • Blair C. Jackson, EVP and COO since 2021, appointed CEO effective August 1, 2026, bringing operational leadership and prior strategic roles
- • Pops to receive $75,000 monthly retainer as Senior Advisor plus $40,000 pro-rated non-executive Chairman fee, 2026 pro-rated bonus, and $2.69M pro-rated RSU award
- • Outstanding equity awards for Pops continue vesting based on service, with extended post-service vesting and exercise periods up to 21 months after board departure
- • Equity awards to fully vest upon change in control or sale event during post-service period; legal fees reimbursed up to $60,000 for transition-related expenses
Item 7.01 · Regulation FD Disclosure
- • CEO transition announced: Mr. Pops retiring, Mr. Jackson named successor effective immediately
- • Leadership change could signal new strategic direction or operational priorities
- • Market may react to leadership stability and investor confidence implications
- • Press release filed as Exhibit 99.1 provides full details of the transition
Other Alkermes plc. 8-K Filings
Get deeper insights on Alkermes plc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.